MCID: NNS003
MIFTS: 30

Non-Secretory Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Non-Secretory Myeloma

MalaCards integrated aliases for Non-Secretory Myeloma:

Name: Non-Secretory Myeloma 12 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9547
UMLS 74 C0456845

Summaries for Non-Secretory Myeloma

MalaCards based summary : Non-Secretory Myeloma is related to myeloma, multiple and indolent myeloma. An important gene associated with Non-Secretory Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and Reelin Pathway (Cajal-Retzius cells). The drugs Bortezomib and Pomalidomide have been mentioned in the context of this disorder. Affiliated tissues include skin.

Related Diseases for Non-Secretory Myeloma

Diseases related to Non-Secretory Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 28.7 ALB B2M CD19 CD38 MYOM2 NCAM1
2 indolent myeloma 10.4 B2M MYOM2
3 extramedullary plasmacytoma 10.4 B2M MYOM2
4 amyloid tumor 10.3 B2M MYOM2
5 prostate squamous cell carcinoma 10.3 B2M SMUG1
6 immunodeficiency 43 10.3 ALB B2M
7 uterine corpus sarcoma 10.3 CD38 SMUG1
8 orthostatic proteinuria 10.3 ALB B2M
9 commensal bacterial infectious disease 10.3 MYOM2 SETBP1
10 cecum adenocarcinoma 10.3 B2M SMUG1
11 diffuse glomerulonephritis 10.3 ALB B2M
12 gastrointestinal tuberculosis 10.2 ALB SMUG1
13 danubian endemic familial nephropathy 10.2 ALB B2M
14 hypersensitivity reaction type iv disease 10.2 MYOM2 SMUG1
15 hepatic tuberculosis 10.2 ALB SMUG1
16 hemorrhagic fever 10.2 ALB B2M
17 klatskin's tumor 10.2 ALB SMUG1
18 acute kidney tubular necrosis 10.2 ALB B2M
19 tuberculous peritonitis 10.2 ALB SMUG1
20 pericardium disease 10.2 ALB SMUG1
21 invasive malignant thymoma 10.2 CD19 CD38
22 xanthogranulomatous pyelonephritis 10.1 ITGAX SMUG1
23 bone marrow cancer 10.1 B2M CD38 MYOM2
24 gallbladder small cell carcinoma 10.1 NCAM1 SMUG1
25 b cell prolymphocytic leukemia 10.1 CD19 CD38
26 prolymphocytic leukemia 10.1 CD19 CD38
27 meningoencephalitis 10.1 ALB B2M
28 gamma heavy chain disease 10.1 CD19 CD38
29 granulomatous myositis 10.1 NCAM1 SMUG1
30 mediastinal cancer 10.1 NCAM1 SMUG1
31 b-cell expansion with nfkb and t-cell anergy 10.1 B2M CD38
32 hemorrhagic fever with renal syndrome 10.1 ALB B2M
33 pleural disease 10.1 ALB SMUG1
34 bladder lymphoma 10.1 CD19 ITGAX
35 malignant skin fibrous histiocytoma 10.1 NCAM1 SMUG1
36 small intestine lymphoma 10.1 B2M CD19 ITGAE
37 malignant dermis tumor 10.1 NCAM1 SMUG1
38 selective igg deficiency disease 10.0 CD19 NCAM1
39 pediatric lymphoma 10.0 NCAM1 SMUG1
40 acquired immunodeficiency syndrome 10.0 ALB B2M CD38
41 pericoronitis 10.0 CD19 NCAM1
42 rhinoscleroma 10.0 CD19 NCAM1
43 intestinal disease 10.0 ALB DDX53 SMUG1
44 plasma protein metabolism disease 10.0 CD19 CD38 MYOM2
45 gastrointestinal system cancer 10.0 ALB DDX53 SMUG1
46 gastrointestinal system disease 10.0 ALB DDX53 SMUG1
47 lymphoma, hodgkin, classic 10.0 CD19 SMUG1
48 esophageal disease 10.0 ALB SMUG1
49 acute kidney failure 10.0 ALB B2M
50 myelodysplastic syndrome 9.9

Graphical network of the top 20 diseases related to Non-Secretory Myeloma:



Diseases related to Non-Secretory Myeloma

Symptoms & Phenotypes for Non-Secretory Myeloma

Drugs & Therapeutics for Non-Secretory Myeloma

Drugs for Non-Secretory Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
2
Pomalidomide Approved Phase 3,Phase 2 19171-19-8
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
4
Lenalidomide Approved Phase 3 191732-72-6 216326
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
6 interferons Phase 3
7 Angiogenesis Inhibitors Phase 3,Phase 2
8 Angiogenesis Modulating Agents Phase 3,Phase 2
9 Peripheral Nervous System Agents Phase 3,Phase 2
10 Anti-Bacterial Agents Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 3,Phase 2
12 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
13 Hormones Phase 3,Phase 2
14
protease inhibitors Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 2
16 Autonomic Agents Phase 3,Phase 2
17 BB 1101 Phase 3,Phase 2
18 Immunosuppressive Agents Phase 3,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3,Phase 2
20 Hormone Antagonists Phase 3,Phase 2
21 Immunologic Factors Phase 3,Phase 2
22 Antiemetics Phase 3,Phase 2
23 Gastrointestinal Agents Phase 3,Phase 2
24 glucocorticoids Phase 3,Phase 2
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
26
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
27
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
30
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
31
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Histone Deacetylase Inhibitors Phase 2
34 Antineoplastic Agents, Alkylating Phase 2
35 Vaccines Phase 2
36 Alkylating Agents Phase 2
37 Antirheumatic Agents Phase 2
38 Bendamustine Hydrochloride Phase 2
39 Protective Agents Phase 2
40 Neuroprotective Agents Phase 2
41 Methylprednisolone Acetate Phase 2
42 Prednisolone acetate Phase 2
43
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
44
Sodium Citrate Approved, Investigational Phase 1 68-04-2
45
Ixazomib Approved, Investigational Phase 1 1072833-77-2
46
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1 77-92-9 311
48
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
49 Protein Kinase Inhibitors Phase 1
50 Proteasome Inhibitors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) Completed NCT00732641 Phase 3 Peginterferon
2 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Completed NCT01311687 Phase 3 pomalidomide;Dexamethasone
3 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
4 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 2 panobinostat;bortezomib;dexamethasone
5 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma Completed NCT02011113 Phase 2 Pomalidomide;Dexamethasone
6 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
7 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Completed NCT01849848 Phase 2 SyB L-0501
8 Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma Terminated NCT01179490 Phase 2 SyB L-0501;prednisolone
9 Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Completed NCT00303797 Phase 1 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;sorafenib tosylate
10 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed NCT00963820 Phase 1 Ixazomib citrate

Search NIH Clinical Center for Non-Secretory Myeloma

Genetic Tests for Non-Secretory Myeloma

Anatomical Context for Non-Secretory Myeloma

MalaCards organs/tissues related to Non-Secretory Myeloma:

42
Skin

Publications for Non-Secretory Myeloma

Articles related to Non-Secretory Myeloma:

(show all 16)
# Title Authors Year
1
Non-Secretory Myeloma: Ready for a new Definition? ( 28894562 )
2017
2
Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. ( 27504298 )
2016
3
A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. ( 26003102 )
2015
4
Non-secretory myeloma: clinical and biologic implications. ( 24282995 )
2013
5
Non-secretory myeloma: one, two, or more entities? ( 24282994 )
2013
6
Non-secretory myeloma: a clinician's guide. ( 24282993 )
2013
7
Polymyositis associated with non-secretory myeloma - a case report. ( 23393512 )
2011
8
Non-secretory myeloma: a rare variant of multiple myeloma. ( 18803898 )
2008
9
Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. ( 10634653 )
2000
10
Twelve-year profile of a non-secretory myeloma with amyloidosis. ( 2282322 )
1990
11
Skin involvement in non-secretory myeloma. ( 3407670 )
1988
12
Hypercalcaemia in a patient with non-secretory myeloma. ( 3211820 )
1988
13
Non-secretory myeloma. ( 3793705 )
1986
14
Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing. ( 3926829 )
1985
15
Disseminated intravascular coagulation in a case of non-secretory myeloma. ( 6511287 )
1984
16
Intact and fragmented intracellular immunoglobulin in a case of non-secretory myeloma. ( 1123437 )
1975

Variations for Non-Secretory Myeloma

Expression for Non-Secretory Myeloma

Search GEO for disease gene expression data for Non-Secretory Myeloma.

Pathways for Non-Secretory Myeloma

GO Terms for Non-Secretory Myeloma

Cellular components related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 B2M CD38 ITGAX NCAM1
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CXCL9 ITGAE ITGAX NCAM1
3 integrin complex GO:0008305 8.96 ITGAE ITGAX

Biological processes related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 retina homeostasis GO:0001895 8.96 ALB B2M
2 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 8.62 CD19 CXCL9

Sources for Non-Secretory Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....